Whittier Trust Co. Sells 311 Shares of Gilead Sciences, Inc. $GILD

Whittier Trust Co. lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,041 shares of the biopharmaceutical company’s stock after selling 311 shares during the quarter. Whittier Trust Co.’s holdings in Gilead Sciences were worth $4,328,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of GILD. Price T Rowe Associates Inc. MD lifted its position in shares of Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after acquiring an additional 11,156,382 shares during the period. Nuveen LLC bought a new stake in shares of Gilead Sciences in the 1st quarter worth approximately $620,415,000. Kingstone Capital Partners Texas LLC bought a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $238,083,000. Los Angeles Capital Management LLC lifted its position in shares of Gilead Sciences by 422.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after buying an additional 2,040,261 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after buying an additional 1,942,433 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on GILD. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Cantor Fitzgerald raised their target price on Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Rothschild & Co Redburn raised their target price on Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $121.14.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares of the company’s stock, valued at approximately $66,013,726.98. This trade represents a 1.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the sale, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at $18,545,054.40. This trade represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,500 shares of company stock valued at $8,281,540. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 0.8%

GILD stock opened at $124.08 on Wednesday. The business has a fifty day moving average price of $115.35 and a 200 day moving average price of $110.71. Gilead Sciences, Inc. has a fifty-two week low of $85.60 and a fifty-two week high of $124.61. The stock has a market capitalization of $153.96 billion, a price-to-earnings ratio of 24.72, a P/E/G ratio of 0.84 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same period last year, the firm posted $2.01 EPS. The business’s revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.